Data completeness
0/8 — Limited
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
YUTOPAR (ritodrine hydrochloride) is an injectable beta-2 adrenergic agonist indicated for the management of preterm labor in pregnant women. It works by stimulating beta-2 receptors on uterine smooth muscle to inhibit uterine contractions. The drug is currently in pre-launch phase under AstraZeneca sponsorship.
Pre-Launch
Early-stage product with significant hiring activity (912 linked roles) suggests AstraZeneca is building pre-launch infrastructure across multiple functions.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
YUTOPAR represents a rare launch-phase opportunity with substantial hiring momentum across regulatory, medical, and data science functions. Working on this product offers early-career positioning in a specialized therapeutic area with limited competition and the chance to shape commercial strategy from inception.
Collaborative Marketing ManagerSHE Advisor
Worked on YUTOPAR at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.